Which RhD alleles are risk factors stimulating allo- anti-D?
  
View Full Text  View/Add Comment  Download reader
DOI:10.46701/APJBG.2017032017043
KeyWord:RhD-negative, anti-D, alloimmunization, partial D, Del
                       
AuthorInstitution
Fang Yan Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
Yu-Shiang Lin Department of Clinical Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China; College of Medicine. Aerospace Center Hospital, Beijing, 100076, China.
Zhiyuan Xu Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
Xiaofei Li Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
Lei Zhang Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
Ye Zhang Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
SuFang Liu Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
TianHong Miao Blood Group Lab, Beijing Red Cross Blood Center, Beijing, 100088, China
Hits: 2468
Download times: 2255
Abstract:
      The aim of this study was to identify the specific RhD alleles that are risk factors for stimulating allo-anti-D and develop a precise strategy for blood transfusion. To confirm the D phenotype, red blood cells suspended in saline should react to serological anti-D from three manufacturers. An antibody screen test, a saline phase test and a micro-column test were conducted to identify allo-anti-D and other allo-antibodies. RhD alleles were genotyped by PCR using sequence-specific primers. Seven hundred subjects who were either pregnant or had undergone transfusion were enrolled in our study; however, 28 samples were excluded because their RhD alleles were normal, as revealed by tests using genotyping kits. A total of 498 cases (74.1%) were RhD-null (lacking exons 1–10 of RhD), 336 were DEL RhD 1227A (20.2%), and 38 were RHD-CE (2-9) -D (5.6%). There were 136 cases (20.2%) with allo-anti-D among the 672 cases, with an allo-anti-D prevalence of 126 cases (25.3%) in 498 cases that were RhD-null, followed by 10 cases (26.3%) among 38 cases with RHD-CE (2-9) -D, and none in 366 cases with RhD1227A. RhD genetic polymorphism was observed in RhD-negative individuals. We concluded that RhD-null and partial D are risk factors for alloimmunization to the D antigen and should be transfused with Rh-negative blood. RHD1227A recipients can be transfused with RhD-positive blood. Pregnant women with the d/d and D-CE(2-9)-D alleles require appropriate anti-D prophylaxis and RhD1227A may induce a higher tolerance.
Close